within Pharmacolibrary.Drugs.ATC.A;

model A10BD21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.21,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008833333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Saxagliptin and dapagliflozin is a fixed-dose combination drug used to treat type 2 diabetes mellitus in adults. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor and dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This combination helps to improve glycemic control by targeting different mechanisms. The drug is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>No population pharmacokinetic models or detailed PK parameters published in the literature for the fixed-dose combination. Individual PK parameters for saxagliptin and dapagliflozin are available but no combined PK study found. Estimates below are based on typical adult values for each component after oral administration.</p><h4>References</h4><ol><li>Simeon I Taylor, Zhinous Shahidzadeh Yazdi, Amber L Beitelshees,Pharmacological treatment of hyperglycemia in type 2 diabetes.,The Journal of clinical investigation,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33463546/'>https://pubmed.ncbi.nlm.nih.gov/33463546/</a></li><li>Andr√© J Scheen,Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.,Expert review of clinical pharmacology,2017<a href='https://pubmed.ncbi.nlm.nih.gov/28984487/'>https://pubmed.ncbi.nlm.nih.gov/28984487/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BD21;
